Fig. 6 | Scientific Reports

Fig. 6

From: Characterization of RNF144B and PPP2R2A identified by a novel approach using TCGA data in ovarian cancer

Fig. 6

Sensitivity to PARP inhibitors and expression of PPP2R2A in patients with HGSOC. (a) Ovarian cancer cell lines with differential expression of PPP2R2A were treated with Niraparib (50 µm) and cell proliferation assays were performed using an MTT reagent. Two independent experiments were performed in triplicate. Statistical significance was calculated using the two-tailed Student’s t-test; p = 0.0001. Immunohistochemical control staining of human PPP2R2A. Representative immunostaining of PPP2R2A in ovarian surface epithelium (OSE) (b) fallopian tube, and HGSOC tumors. (c) PPP2R2A protein expression levels in control and HGSOC tissues. p < 0.0001 Magnification 40X.

Back to article page